Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00695864 · ClinicalTrials.gov registry record · NA
Effect of Ondansetron for Withdrawal Symptoms
A NA study of Substance Withdrawal Syndrome, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT00695864: Completed NA study of Substance Withdrawal Syndrome, sponsored by Stanford University.
NCT00695864 is a NA study of Substance Withdrawal Syndrome that has completed, run by Stanford University. The registered enrollment target is 31 participants, below the 186-participant average among 3 other Substance Withdrawal Syndrome trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00695864, a NA study of Substance Withdrawal Syndrome, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve withdrawal symptoms experienced while the patient is being weaned off opioid medications. This medication has shown anecdotal evidence of being affective for the treatment of withdrawal symptoms and we hope to determine whether this is affective.
Primary Outcome
Subjective Opioid Withdrawal Scale: Participants were asked to rate, from 0 to 4, their experience of 15 withdrawal symptoms. Scores for each participant were derived from the sum of their withdrawal symptoms score (minimum:0, maximum: 60). A higher score indicates more symptoms experienced and/or at a greater degree of severity.
Conditions Studied
Interventions
- DRUG Ondansetron and Placebo crossover
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-07 |
| Phase | NA |
What the finished NCT00695864 record still lists
NCT00695864 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 186-participant average among 3 other Substance Withdrawal Syndrome trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Substance Withdrawal Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Ondansetron and Placebo crossover is the first listed.
NCT00695864 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00695864 about?
NCT00695864 is a clinical study titled "Effect of Ondansetron for Withdrawal Symptoms". We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve withdrawal symptoms experienced while the patient is being weaned off opioid medications. This medication has shown anecdotal evidence of being affective for the treatment of withdrawal symptoms and we hope to...
What is the current status of trial NCT00695864?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2008-05. Estimated completion is 2009-07.
What conditions does trial NCT00695864 study?
This clinical trial studies the following conditions: Substance Withdrawal Syndrome.
What interventions are being tested in trial NCT00695864?
The interventions under investigation include: Ondansetron and Placebo crossover (DRUG).
Who is sponsoring clinical trial NCT00695864?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00695864 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Withdrawal Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia